Compare Illumina, Inc. (ILMN) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs US Bancorp — how do they compare? Illumina, Inc. trades at $189.41 (market cap $27.94B), while US Bancorp trades at $63.48 (market cap $98.36B). The key difference: US Bancorp is far larger — about 3.5× Illumina, Inc.'s market cap, and US Bancorp pays a 3.29% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | USB | |
|---|---|---|
Market Cap | $27.94B | $98.36B |
Sector | Health | Financials |
52-Week High | $194.33 | $64.01 |
52-Week Low | $91.00 | $43.94 |
Enterprise Value | $29.33B | — |
Dividend Yield | — | 3.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
U.S. Bancorp (USB) trades at $63.09, down 0.08% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $69.70. Recent Q2 2026 earnings beat expectations with EPS of $1.35, driven by loan growth and fee income. Revenue reached a record $28.54B in 2025, with net income margin improving to 27.61%. The stock shows strong institutional support with 47.92% of analysts rating it a Buy.
Outlook remains positive due to earnings momentum and dividend yield near 3%, but risks include rising debt-to-asset ratios and macroeconomic sensitivity. Upside potential exists if loan growth and digital banking adoption continue, though investor caution is warranted given RSI levels indicating mild overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
